Fibrates

Name: Fibrates — Cardiovascular pharmacology
Creator: LearnDrugs

Verified · Oct 2026

Fibrates act on a nuclear receptor (PPAR-α) that reprograms lipid handling — more lipoprotein lipase, less apo C-III, more β-oxidation — so they lower triglycerides far more than LDL. The two drugs differ in one key way: gemfibrozil inhibits OATP1B1, a hepatic transporter for many statins, while fenofibrate changes statin levels little.

Nursing view → administration, monitoring and patient teaching

Compare: Lipid-lowering agents compared →

Drugs

fenofibrate Antara, Lipofen

gemfibrozil Lopid

Mechanism

Fenofibrate is hydrolyzed to fenofibric acid, a PPAR-α agonist that activates lipoprotein lipase and reduces apolipoprotein C-III production, increasing lipolysis and clearance of triglyceride-rich particles. Gemfibrozil inhibits peripheral lipolysis and hepatic free-fatty-acid extraction, reducing hepatic triglyceride production, and inhibits synthesis and increases clearance of VLDL apolipoprotein B.

Triglyceride transport and PPAR-α

The liver packages triglycerides into VLDL and the intestine into chylomicrons. Lipoprotein lipase (LPL) hydrolyzes their triglycerides, turning VLDL into IDL, which hepatic lipase converts to LDL. Apolipoprotein C-III inhibits LPL.

PPAR-α is a ligand-activated transcription factor of the nuclear-receptor family that controls fatty-acid β-oxidation and lipid metabolism. Fibric acids bind it, and the result is more LPL (in adipose tissue and muscle), less apo C-III, more fatty-acid oxidation and HDL synthesis — triglyceride-rich particles are cleared faster and less triglyceride is made. VLDL falls, and plasma triglycerides drop by 30–60%.

Fenofibrate itself is a prodrug: esterases convert it to fenofibric acid, the PPAR-α ligand. Gemfibrozil’s effect was first described in other terms — less peripheral lipolysis, less hepatic free-fatty-acid uptake and less VLDL apolipoprotein B production — and it, too, activates PPAR-α.

Loading diagram…

PPAR-α activation clears triglyceride-rich lipoproteins.

Why gemfibrozil is the dangerous statin partner

Many statins are substrates of the hepatic transporter OATP1B1 — atorvastatin among them — and OATP1B1 inhibitors raise exposure to simvastatin acid. Gemfibrozil inhibits OATP1B1, so statin levels rise on top of the fibrate’s own myopathy risk, which is why gemfibrozil with simvastatin is contraindicated and rhabdomyolysis with acute renal failure has followed the combination. Gemfibrozil is also a strong CYP2C8 inhibitor and, in vitro, inhibits UGT1A1 and UGT1A3 and several other CYPs.

Fenofibric acid is cleared mainly by glucuronidation and has minimal effect on cytochrome P450 activity, and fenofibrate changed atorvastatin and pravastatin exposure only modestly, so it lacks gemfibrozil’s pharmacokinetic interaction. Its label still says to avoid combining it with a statin unless the benefit outweighs the added myopathy risk. Gemfibrozil’s OATP1B1 and CYP2C8 inhibition also raises repaglinide exposure about 8-fold, causing severe hypoglycemia.

Loading diagram…

Gemfibrozil raises statin exposure through OATP1B1; fenofibrate changes it little.

Gallstones, rising LDL and creatinine

Fibrates may increase cholesterol excretion into bile — the mechanism behind cholelithiasis and the contraindication in pre-existing gallbladder disease. Stones or sludge obstructing the common bile duct are one proposed route to fibrate-associated pancreatitis.

LDL can rise when patients with very high triglycerides (Type IV) are treated, even as VLDL falls. Fenofibrate also raises serum creatinine reversibly — the clinical significance is unknown — and, because fibrates are cleared mainly by the kidney, severe renal impairment is a contraindication.

Comparing the drugs

Fenofibrate vs gemfibrozil

Drug	Active form	Half-life	Clearance	Statin pairing
Fenofibrate	Prodrug → fenofibric acid (esterases)	About 20–23 h (once daily)	Glucuronidated; renal excretion; minimal CYP effect	Possible with caution (avoid unless benefit outweighs risk)
Gemfibrozil	Active drug	About 1.5 h (twice daily, before meals)	Hepatic oxidation; ~70% urine, mostly as glucuronide	Simvastatin contraindicated; avoid rosuvastatin; OATP1B1/CYP2C8 inhibitor

Pharmacokinetics

Fenofibrate: a prodrug cleared as a glucuronide — fenofibrate: Esterases rapidly hydrolyze fenofibrate, so no unchanged drug is found in plasma; fenofibric acid is about 99% protein-bound, reaches steady state within about a week, has a half-life of about 23 hours, and is conjugated with glucuronic acid and excreted in urine.
Fenofibrate formulations and food — fenofibrate: Fenofibrate is insoluble in water; micronized and nanocrystal forms improve bioavailability, and food increases absorption for most formulations (a high-fat meal raised Antara’s AUC by 26%).
Gemfibrozil: short-acting, best before meals — gemfibrozil: Gemfibrozil is completely absorbed, peaks in 1–2 hours and has a half-life of about 1.5 hours; absorption is faster and greater when it is taken half an hour before meals. About 70% is excreted in urine, mostly as the glucuronide, with less than 2% unchanged.
Fenofibrate and the cytochrome P450 system — fenofibrate: Fenofibrate and fenofibric acid do not inhibit CYP3A4, CYP2D6, CYP2E1 or CYP1A2 and are weak CYP2C8 and mild-to-moderate CYP2C9 inhibitors; with fenofibrate, atorvastatin exposure fell 17% and pravastatin exposure rose 13%.
Both: highly protein-bound, renally cleared: Both are highly bound to plasma proteins (gemfibrozil has potential for displacement interactions), and renal excretion is the primary elimination route of fibrates — the basis of the severe-renal-impairment contraindication and the caution with nephrotoxic drugs such as cyclosporine.

Uses & drug choice

Fenofibrate and gemfibrozil as adjuncts to diet for severe hypertriglyceridemia (fenofibrate: TG ≥ 500 mg/dL; gemfibrozil: Types IV and V hyperlipidemia with a risk of pancreatitis)
Fenofibrate to lower elevated LDL-C in primary hyperlipidemia when recommended LDL-lowering therapy is not possible
Gemfibrozil to reduce coronary heart disease risk only in Type IIb patients without coronary disease (low HDL with high LDL and triglycerides; inadequate response to other measures)

Severe hypertriglyceridemia (TG ≥ 500 mg/dL) after secondary causes and diet are addressed → A fibrate as an adjunct to diet

PPAR-α activation lowers triglycerides by 30–60% by clearing VLDL; the labels require diet and correction of causes such as diabetes, hypothyroidism, alcohol and estrogen.

A patient on a statin who also needs triglyceride lowering → Fenofibrate (fenofibric acid), not gemfibrozil

Gemfibrozil inhibits OATP1B1 and is contraindicated with simvastatin; fenofibrate changes statin exposure little and is not contraindicated with statins, but its label says to avoid the combination unless the benefit outweighs the added myopathy risk.

Type 2 diabetes treated with repaglinide → Not gemfibrozil

Gemfibrozil raises repaglinide exposure about 8-fold and causes severe hypoglycemia — the combination is contraindicated.

Known gallstones or gallbladder disease → Avoid fibrates

Fibrates increase cholesterol excretion into bile; pre-existing gallbladder disease is a contraindication for both.

Severe renal impairment (eGFR < 30, dialysis) → Avoid fibrates

Renal excretion is the main elimination route; both labels contraindicate severe renal impairment.

Adverse effects

Common

Abnormal liver tests, abdominal pain, raised CK and constipation (fenofibrate); dyspepsia, abdominal pain and diarrhea (gemfibrozil).

Myopathy and rhabdomyolysis

Muscle pain, tenderness or weakness with raised CK — rhabdomyolysis can follow, especially with a statin.

Liver injury

Serious drug-induced liver injury with fenofibrate; raised liver tests with gemfibrozil.

Gallstones and pancreatitis

Gallstones (cholelithiasis) with either fibrate; pancreatitis reported with fenofibrate.

Kidney effects

Rises in serum creatinine with fenofibrate; worsening renal insufficiency with gemfibrozil.

Hypersensitivity (fenofibrate)

Anaphylaxis, angioedema and severe skin reactions (SJS, TEN, DRESS) with fenofibrate.

Blood counts, HDL and clots

Early falls in hemoglobin, hematocrit and white cells (both); paradoxical HDL fall and more venous thromboembolism (fenofibrate).

Myopathy and rhabdomyolysis: Fibrates can cause myopathy alone; with a statin the risk rises, and with gemfibrozil statin exposure also climbs because OATP1B1 is inhibited. Age, hypothyroidism, renal impairment and colchicine add to the risk.
Cholelithiasis: More cholesterol is excreted into bile, favoring cholesterol stones.
Pancreatitis: It may reflect failure to control severe hypertriglyceridemia, a direct drug effect, or gallstones or sludge obstructing the common bile duct.
Hypoglycemia with repaglinide (gemfibrozil): Gemfibrozil’s CYP2C8 and OATP1B1 inhibition raises repaglinide exposure about 8-fold and prolongs its glucose-lowering effect.
Bleeding with warfarin: Fibrates potentiate coumarin anticoagulants and prolong the PT/INR (gemfibrozil is highly protein-bound, with potential for displacement interactions).

Interactions

Statins

More myopathy and rhabdomyolysis. Gemfibrozil + simvastatin is contraindicated and gemfibrozil + rosuvastatin should be avoided; fenofibrate + a statin only if the benefit outweighs the risk, with monitoring for muscle symptoms.

Repaglinide (gemfibrozil)

Contraindicated — repaglinide exposure rises about 8-fold, with prolonged, severe hypoglycemia.

Warfarin and other coumarin anticoagulants

Fibrates potentiate the anticoagulant effect and prolong the PT/INR — the warfarin dose is reduced and the INR checked frequently until stable.

Colchicine

Adds to myopathy risk, especially in older patients or those with renal dysfunction.

CYP2C8 and OATP1B1 substrates (gemfibrozil)

Gemfibrozil raises their levels — for example pioglitazone, montelukast and paclitaxel (CYP2C8), and glyburide and ezetimibe (OATP1B1); dasabuvir and selexipag are contraindicated.

Bile-acid binding resins

Bind fibrates in the gut — give fenofibrate at least 1 hour before or 4–6 hours after the resin, and gemfibrozil at least 2 hours apart.

Cyclosporine, tacrolimus and other nephrotoxic drugs (fenofibrate)

Risk of worsening renal function, since fibrates are cleared by the kidney — monitor renal function.

Contraindications

Severe renal impairment (fenofibrate: including end-stage renal disease and dialysis; gemfibrozil: severe renal dysfunction) — Labeled contraindications — fibrates are cleared mainly by the kidney.
Active liver disease or unexplained persistent liver-test abnormalities (fenofibrate); hepatic dysfunction including primary biliary cirrhosis (gemfibrozil) — Labeled contraindications — fibrates can injure the liver.
Pre-existing gallbladder disease — Labeled contraindication for both drugs — fibrates can cause gallstones.
Gemfibrozil with simvastatin, repaglinide, dasabuvir or selexipag — Labeled contraindications — gemfibrozil raises their exposure (OATP1B1: simvastatin, repaglinide; CYP2C8: dasabuvir; selexipag’s active metabolite about 11-fold), with rhabdomyolysis, severe hypoglycemia or QT prolongation as the risks.
A fibrate with a statin (other than gemfibrozil with simvastatin) use caution — Not contraindicated, but the risk of myopathy and rhabdomyolysis rises; avoid unless the benefit clearly outweighs it (avoid gemfibrozil with rosuvastatin).
Breastfeeding use caution — Fenofibrate is likely present in human milk and could disrupt infant lipid metabolism, so breastfeeding is avoided during Antara treatment and for 5 days after the last dose; with gemfibrozil, either nursing or the drug is stopped.

High-yield

Nuclear receptor activated by fibrates PPAR-α

Apolipoprotein that inhibits lipoprotein lipase and is lowered by fibrates Apo C-III

Fibrate contraindicated with simvastatin and repaglinide Gemfibrozil (OATP1B1 and CYP2C8 inhibitor)

Fibrate prodrug hydrolyzed by esterases to its active acid Fenofibrate (→ fenofibric acid)

Gallstones in a patient started on a lipid drug for very high triglycerides Fibrate — more cholesterol excreted into bile

LDL rises after starting gemfibrozil for Type IV hypertriglyceridemia A labeled effect — LDL-cholesterol often rises as triglycerides fall

Lipid drug whose label requires frequent INR checks with warfarin Fibrates (potentiate coumarins)

PPAR-α: Lipase up, C-III down, burn the fat

Lipase up — more lipoprotein lipase hydrolyzes VLDL and chylomicron triglycerides
C-III down — less of the LPL inhibitor
Burn the fat — more fatty-acid β-oxidation, less triglyceride made

Net effect: triglycerides fall 30–60%, HDL rises, LDL changes least.

GEMfibrozil GEts in the way

Gets in the way of OATP1B1 (statin and repaglinide levels climb) and CYP2C8 (repaglinide); UGT1A1/1A3 in vitro
Fenofibric acid is glucuronidated with little CYP effect — the fibrate that can be paired with a statin when the benefit outweighs the risk

Gemfibrozil + simvastatin and gemfibrozil + repaglinide are contraindicated.

Practice questions

Q1A 58-year-old man taking simvastatin is started on gemfibrozil for triglycerides of 900 mg/dL. Three weeks later he has diffuse muscle pain, dark urine and a creatine kinase of 45,000 U/L, with a rising creatinine.

What best explains the severity of this reaction?

A.Gemfibrozil activates PPAR-α in skeletal muscle, causing direct necrosis
B.Gemfibrozil inhibits OATP1B1, raising statin exposure on top of the fibrate’s own myopathy risk
C.Simvastatin induces gemfibrozil metabolism to a toxic glucuronide
D.Any fibrate would raise simvastatin exposure this much
E.Gemfibrozil lowers apo C-III in muscle membranes

Show answer

B. Gemfibrozil inhibits OATP1B1, raising statin exposure on top of the fibrate’s own myopathy risk — Fibrates can cause myopathy alone, and the risk rises with statins. Gemfibrozil also inhibits OATP1B1, a hepatic transporter of simvastatin and other statins, so statin exposure increases — which is why gemfibrozil with simvastatin is contraindicated and the combination has led to rhabdomyolysis and acute renal failure. Fenofibrate, by contrast, changes statin exposure only modestly. Fibrates are metabolized mainly by glucuronidation, and their lipid effects — activating PPAR-α, increasing lipoprotein lipase and lowering apo C — clear triglyceride-rich lipoproteins; what makes this case severe is the OATP1B1 interaction on top of the fibrate’s own myopathy risk.

Q2A 52-year-old woman with Type IV hyperlipoproteinemia (triglycerides 1,200 mg/dL) is started on gemfibrozil with diet. Eight weeks later her triglycerides are 450 mg/dL, but her LDL has risen from 90 to 120 mg/dL.

How is the LDL change best interpreted?

A.Gemfibrozil blocks the LDL receptor
B.Gemfibrozil increases hepatic VLDL apoB production
C.New hypothyroidism caused by gemfibrozil
D.A recognized effect: treating Type IV hypertriglyceridemia with gemfibrozil often raises LDL-cholesterol
E.Gemfibrozil inhibits HMG-CoA reductase less than expected

Show answer

D. A recognized effect: treating Type IV hypertriglyceridemia with gemfibrozil often raises LDL-cholesterol — Gemfibrozil lowers triglycerides and VLDL, but its label notes that treating elevated triglycerides due to Type IV hyperlipoproteinemia often results in a rise in LDL-cholesterol. Gemfibrozil acts through PPAR-α, inhibits peripheral lipolysis and decreases hepatic VLDL apoB production; it does not act on LDL receptors or HMG-CoA reductase, and hypothyroidism is a secondary cause of high triglycerides to look for before treatment, not an effect of the drug.

Q3A 64-year-old man on fenofibrate develops right-upper-quadrant pain after fatty meals; ultrasound shows gallstones.

Which mechanism links the drug to his gallstones?

A.Increased cholesterol excretion into bile
B.Reduced bile acid synthesis from CYP2C8 inhibition
C.Gallbladder hypomotility from PPAR-γ activation
D.Hemolysis producing pigment stones
E.Calcium bilirubinate precipitation from renal impairment

Show answer

A. Increased cholesterol excretion into bile — Fibrates may increase cholesterol excretion into bile, leading to cholelithiasis. The fibrate is stopped when gallstones are found, and pre-existing gallbladder disease is a contraindication. CYP2C8 inhibition is not the link: fenofibrate is only a weak CYP2C8 inhibitor, and the CYP2C8 inhibitor that matters for interactions such as repaglinide is gemfibrozil.

Q4A 60-year-old woman with type 2 diabetes treated with repaglinide is found to have triglycerides of 800 mg/dL. Her clinician considers adding a fibrate.

Why should gemfibrozil be avoided?

A.It worsens insulin resistance through PPAR-γ
B.It antagonizes repaglinide at the sulfonylurea receptor
C.It causes lactic acidosis with repaglinide
D.It increases renal glucose excretion
E.It raises repaglinide exposure about 8-fold through CYP2C8 and OATP1B1 inhibition, causing severe hypoglycemia

Show answer

E. It raises repaglinide exposure about 8-fold through CYP2C8 and OATP1B1 inhibition, causing severe hypoglycemia — Gemfibrozil is a strong CYP2C8 inhibitor and an OATP1B1 inhibitor; repaglinide AUC rose 8.1-fold with prolonged hypoglycemic effects, so the combination is contraindicated. The problem is pharmacokinetic, not an action at repaglinide’s receptor; gemfibrozil’s lipid effects come from PPAR-α, not PPAR-γ; lactic acidosis is metformin’s boxed warning; and increased urinary glucose excretion is how SGLT2 inhibitors such as empagliflozin work.

More in the Cardiovascular question bank →

Sources

By LearnDrugs

Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.